© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
"Not So Different": Are We Ready for Biosimilar Rituximab in the United States?
It’s widely expected that the United States will see launches of one or both of the FDA-approved rituximab biosimilars, Ruxience and Truxima, in the coming months, but just how ready is the United States to bring these products to the clinic, especially given the fact that subcutaneously administered reference rituximab has taken on such a key place in clinical practice, and given the fact that both biosimilars have so-called “skinny labels” because of issues related to intellectual property and exclusivities?
It’s widely expected that the United States will see launches of one or both of the FDA-approved rituximab biosimilars, Ruxience and Truxima, in the coming months, but just how ready is the United States to bring these products to the clinic, especially given the fact that subcutaneously administered reference rituximab has taken on such a key place in clinical practice, and given the fact that both biosimilars have so-called “skinny labels” because of issues related to intellectual property and exclusivities?
Over the past year, we’ve had the opportunity to explore these questions and more with a variety of experts in the oncology field. This time on the podcast, we’re rounding up some of the key insights they’ve shared.
Read more about Ruxience and Truxima.
